Lannett Company Boston Consulting Group Matrix
See the Bigger Picture
Lannett’s brief BCG Matrix snapshot hints at a portfolio balancing generics and specialty injectables across varying growth and share positions—some SKUs behave like Cash Cows while others show Question Mark potential amid pricing pressure and regulatory risk. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Biosimilar Insulin Glargine
As of late 2025, Lannett’s biosimilar insulin glargine is its top Star after positive phase III results and a BLA filing with FDA in Sep 2025; it targets the $48B global insulin market and U.S. diabetes cohort of ~37 million.
Competing directly with Sanofi’s Lantus, pricing models assume 30–40% discount and potential U.S. peak sales of $800M–$1.2B by 2030; launch and distribution will require $60M–$120M upfront.
High growth prospects stem from payer shifts to lower-cost biologics and formulary wins; if Lannett captures 10–15% U.S. basal insulin share, EBITDA conversion could exceed 25% within 3–5 years.
ADHD Medication Portfolio
Lannett’s ADHD medication portfolio, led by Amphetamine Sulfate, sits in the BCG Stars quadrant due to double-digit prescription growth—national ADHD scripts rose ~12% CAGR 2020–2024 and continued strong demand into 2025.
After Aurobindo’s 2025 acquisition, enhanced U.S. distribution and scale lifted sales; combined channel reach expanded by ~30%, helping revenue for controlled substances grow an estimated 18% year-over-year in 2025.
Market position is strong with ~20–25% share in generic amphetamine supply, but sustained capital expenditure is needed to expand GMP capacity and meet projected 15–20% annual patient demand growth.
Respiratory Generic Pipeline
By end-2025 Lannett’s Respiratory Generic Pipeline, centered on inhaler technologies, moved into a high-growth BCG quadrant as respiratory generics grew ~12% CAGR 2022–25 and Lannett captured ~18% U.S. inhaler market share versus limited rivals.
These high-barrier-to-entry generics support premium margins; Lannett reported respiratory gross margin ~36% in FY2025 and invested $85M in specialized manufacturing in 2023–25 to sustain scale.
Contract Development and Manufacturing Services (CDMO)
Lannett’s Contract Development and Manufacturing Organization (CDMO) is a Star, using its 425,000-square-foot Indiana plant to offer end-to-end high-potency and liquid drug production; revenue from CDMO rose 38% in 2024, driving a larger share of consolidated gross margin.
With 2025 U.S. reshoring trends boosting demand, CDMO utilization climbed to ~88% and new third-party contracts backlog exceeded $210 million, but ongoing capex for tech transfer and scale-up (estimated $25–40 million in 2025) is required to sustain growth.
- 425,000 sq ft Indiana facility
- 2024 CDMO revenue +38%
- 2025 utilization ~88%
- $210M+ contract backlog
- $25–40M 2025 capex need
Liquid Generic Pharmaceuticals
Lannett’s Seymour-approved liquid facility fuels strong growth in liquid generics like Numbrino and multiple elixirs, driving 28% segment revenue growth in 2024 and raising liquid share to 42% of company sales.
With rivals focused on oral solids, Lannett holds a top-3 U.S. share in liquid generics; management plans $45M capex through 2026 to add 6 new liquid SKUs and protect margins.
- 2024 segment revenue: $132M
- YoY growth: 28%
- 2026 planned SKUs: +6
- Capex 2024–26: $45M
- Market share (liquid generics): 42%
Lannett growth play: biosimilar insulin ($800M–$1.2B), ADHD share, strong CDMO backlog
Lannett Stars: biosimilar insulin glargine (BLA Sep 2025; U.S. peak $800M–$1.2B by 2030; $60M–$120M launch capex); ADHD amphetamines (20–25% generic share; 2025 sales +18%); respiratory inhalers (18% U.S. share; GM ~36% FY2025); CDMO (425,000 sq ft; 2024 revenue +38%; 2025 utilization ~88%; $210M backlog; $25–40M capex).
| Asset | Key metric | 2024–25 data |
|---|---|---|
| Insulin glargine | Peak sales | $800M–$1.2B |
| ADHD | Market share | 20–25% |
| Respiratory | Gross margin | 36% |
| CDMO | Backlog | $210M+ |
What is included in the product
Detailed Word Document
Concise BCG assessment of Lannett’s portfolio: Stars to scale, Cash Cows to harvest, Question Marks to evaluate for investment, Dogs to divest.
Customizable Excel Spreadsheet
One-page BCG matrix placing Lannett business units into quadrants for quick strategic decisions.
Cash Cows
Levothyroxine Tablets
Levothyroxine tablets remain a cornerstone of Lannett Company’s revenue, holding an estimated 30–35% U.S. market share in the mature thyroid hormone replacement market as of 2025 and delivering roughly $120–140 million annual sales. This product needs minimal marketing spend and yields high gross margins near 60%, producing steady cash flow that funds R&D for newer biologics. As a classic Cash Cow, levothyroxine provided the liquidity Lannett used during its 2024–2025 post-bankruptcy restructuring to meet debt obligations and restart strategic investment.
Cardiovascular Generics
Lannett’s cardiovascular generics—notably beta-blockers and ACE inhibitors—sit in a low-growth, high-stability segment, with US market growth ~1% annually (2024 IMS Health) and gross margins near 45%.
These drugs show deep penetration across retail and institutional channels, supplying ~12% of national distributor cardiovascular volumes as of FY 2024.
Portfolio cash flow funded 2024 interest payments and directed $48M into the biosimilar R&D pipeline, so the line is actively milked to deleverage and scale biosimilars.
Oxybutynin Portfolio
Oxybutynin tablets and syrups remain market leaders in the mature overactive bladder segment, holding roughly 18–22% U.S. market share in 2025 and generating about $42–48 million annual net revenue for Lannett Company.
Low competitive volatility and minimal capex needs keep gross margins near 60%, so the line consistently produces cash flow and funds R&D and restructuring.
As a predictable liquidity source, oxybutynin supports the reorganized company while management prioritizes complex launches with higher development costs and longer payback periods.
Pain Management Generics
Lannett’s legacy pain management generics, including controlled substances like oxycodone and morphine formulations, still command roughly 20–25% share in select outpatient SKU markets as of 2025, despite low single-digit CAGR in the overall generic opioids sector.
Manufactured at scale in Lannett’s Pennsylvania facilities, these SKUs deliver gross margins near 35–40% and generate steady free cash flow with minimal incremental capital expenditure.
Those cash flows funded about $45–60 million of R&D and M&A earmarked for specialty, high-value generics in 2024–2025, enabling the strategic pivot without diluting operations.
- Market share: ~20–25%
- Sector growth: low single-digit CAGR
- Gross margin: ~35–40%
- 2024–25 strategic funding: $45–60M
Central Nervous System (CNS) Legacy Products
Central Nervous System (CNS) legacy products in Lannett’s portfolio acted as Cash Cows, delivering steady unit volumes in a mature market and generating predictable margins after amortizing development costs years ago.
These assets produced roughly $45–55 million in annual net cash flow during 2023–2024, helping fund restructuring and drove a 12% improvement in operating cash conversion in that period.
- Steady demand: mature CNS indications, low volatility
- High efficiency: minimal R&D, gross margins ~60% in 2024
- Financial role: funded turnaround, ~$50M cash contribution 2023–24
Lannett’s cash cows: $350–360M revenue, ~$150M funding, 35–60% gross margins
Levothyroxine, cardiovascular generics, oxybutynin, opioid generics, and legacy CNS drugs acted as Lannett’s cash cows in 2024–25, collectively generating ~ $350–360M annual revenue and funding ~$150M of restructuring, R&D, and debt service while carrying gross margins of 35–60% across lines.
| Product | 2025 Rev ($M) | Market Share | Gross Margin |
|---|---|---|---|
| Levothyroxine | 120–140 | 30–35% | ~60% |
| Cardio generics | ~80 | ~12% vol | ~45% |
| Oxybutynin | 42–48 | 18–22% | ~60% |
| Opioid generics | ~60 | 20–25% (select SKUs) | 35–40% |
| CNS legacy | 45–55 | mature | ~60% |
Full Transparency, Always
Lannett Company BCG Matrix
The file you're previewing is the exact Lannett Company BCG Matrix you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
Lannett’s brief BCG Matrix snapshot hints at a portfolio balancing generics and specialty injectables across varying growth and share positions—some SKUs behave like Cash Cows while others show Question Mark potential amid pricing pressure and regulatory risk. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Biosimilar Insulin Glargine
As of late 2025, Lannett’s biosimilar insulin glargine is its top Star after positive phase III results and a BLA filing with FDA in Sep 2025; it targets the $48B global insulin market and U.S. diabetes cohort of ~37 million.
Competing directly with Sanofi’s Lantus, pricing models assume 30–40% discount and potential U.S. peak sales of $800M–$1.2B by 2030; launch and distribution will require $60M–$120M upfront.
High growth prospects stem from payer shifts to lower-cost biologics and formulary wins; if Lannett captures 10–15% U.S. basal insulin share, EBITDA conversion could exceed 25% within 3–5 years.
ADHD Medication Portfolio
Lannett’s ADHD medication portfolio, led by Amphetamine Sulfate, sits in the BCG Stars quadrant due to double-digit prescription growth—national ADHD scripts rose ~12% CAGR 2020–2024 and continued strong demand into 2025.
After Aurobindo’s 2025 acquisition, enhanced U.S. distribution and scale lifted sales; combined channel reach expanded by ~30%, helping revenue for controlled substances grow an estimated 18% year-over-year in 2025.
Market position is strong with ~20–25% share in generic amphetamine supply, but sustained capital expenditure is needed to expand GMP capacity and meet projected 15–20% annual patient demand growth.
Respiratory Generic Pipeline
By end-2025 Lannett’s Respiratory Generic Pipeline, centered on inhaler technologies, moved into a high-growth BCG quadrant as respiratory generics grew ~12% CAGR 2022–25 and Lannett captured ~18% U.S. inhaler market share versus limited rivals.
These high-barrier-to-entry generics support premium margins; Lannett reported respiratory gross margin ~36% in FY2025 and invested $85M in specialized manufacturing in 2023–25 to sustain scale.
Contract Development and Manufacturing Services (CDMO)
Lannett’s Contract Development and Manufacturing Organization (CDMO) is a Star, using its 425,000-square-foot Indiana plant to offer end-to-end high-potency and liquid drug production; revenue from CDMO rose 38% in 2024, driving a larger share of consolidated gross margin.
With 2025 U.S. reshoring trends boosting demand, CDMO utilization climbed to ~88% and new third-party contracts backlog exceeded $210 million, but ongoing capex for tech transfer and scale-up (estimated $25–40 million in 2025) is required to sustain growth.
- 425,000 sq ft Indiana facility
- 2024 CDMO revenue +38%
- 2025 utilization ~88%
- $210M+ contract backlog
- $25–40M 2025 capex need
Liquid Generic Pharmaceuticals
Lannett’s Seymour-approved liquid facility fuels strong growth in liquid generics like Numbrino and multiple elixirs, driving 28% segment revenue growth in 2024 and raising liquid share to 42% of company sales.
With rivals focused on oral solids, Lannett holds a top-3 U.S. share in liquid generics; management plans $45M capex through 2026 to add 6 new liquid SKUs and protect margins.
- 2024 segment revenue: $132M
- YoY growth: 28%
- 2026 planned SKUs: +6
- Capex 2024–26: $45M
- Market share (liquid generics): 42%
Lannett growth play: biosimilar insulin ($800M–$1.2B), ADHD share, strong CDMO backlog
Lannett Stars: biosimilar insulin glargine (BLA Sep 2025; U.S. peak $800M–$1.2B by 2030; $60M–$120M launch capex); ADHD amphetamines (20–25% generic share; 2025 sales +18%); respiratory inhalers (18% U.S. share; GM ~36% FY2025); CDMO (425,000 sq ft; 2024 revenue +38%; 2025 utilization ~88%; $210M backlog; $25–40M capex).
| Asset | Key metric | 2024–25 data |
|---|---|---|
| Insulin glargine | Peak sales | $800M–$1.2B |
| ADHD | Market share | 20–25% |
| Respiratory | Gross margin | 36% |
| CDMO | Backlog | $210M+ |
What is included in the product
Detailed Word Document
Concise BCG assessment of Lannett’s portfolio: Stars to scale, Cash Cows to harvest, Question Marks to evaluate for investment, Dogs to divest.
Customizable Excel Spreadsheet
One-page BCG matrix placing Lannett business units into quadrants for quick strategic decisions.
Cash Cows
Levothyroxine Tablets
Levothyroxine tablets remain a cornerstone of Lannett Company’s revenue, holding an estimated 30–35% U.S. market share in the mature thyroid hormone replacement market as of 2025 and delivering roughly $120–140 million annual sales. This product needs minimal marketing spend and yields high gross margins near 60%, producing steady cash flow that funds R&D for newer biologics. As a classic Cash Cow, levothyroxine provided the liquidity Lannett used during its 2024–2025 post-bankruptcy restructuring to meet debt obligations and restart strategic investment.
Cardiovascular Generics
Lannett’s cardiovascular generics—notably beta-blockers and ACE inhibitors—sit in a low-growth, high-stability segment, with US market growth ~1% annually (2024 IMS Health) and gross margins near 45%.
These drugs show deep penetration across retail and institutional channels, supplying ~12% of national distributor cardiovascular volumes as of FY 2024.
Portfolio cash flow funded 2024 interest payments and directed $48M into the biosimilar R&D pipeline, so the line is actively milked to deleverage and scale biosimilars.
Oxybutynin Portfolio
Oxybutynin tablets and syrups remain market leaders in the mature overactive bladder segment, holding roughly 18–22% U.S. market share in 2025 and generating about $42–48 million annual net revenue for Lannett Company.
Low competitive volatility and minimal capex needs keep gross margins near 60%, so the line consistently produces cash flow and funds R&D and restructuring.
As a predictable liquidity source, oxybutynin supports the reorganized company while management prioritizes complex launches with higher development costs and longer payback periods.
Pain Management Generics
Lannett’s legacy pain management generics, including controlled substances like oxycodone and morphine formulations, still command roughly 20–25% share in select outpatient SKU markets as of 2025, despite low single-digit CAGR in the overall generic opioids sector.
Manufactured at scale in Lannett’s Pennsylvania facilities, these SKUs deliver gross margins near 35–40% and generate steady free cash flow with minimal incremental capital expenditure.
Those cash flows funded about $45–60 million of R&D and M&A earmarked for specialty, high-value generics in 2024–2025, enabling the strategic pivot without diluting operations.
- Market share: ~20–25%
- Sector growth: low single-digit CAGR
- Gross margin: ~35–40%
- 2024–25 strategic funding: $45–60M
Central Nervous System (CNS) Legacy Products
Central Nervous System (CNS) legacy products in Lannett’s portfolio acted as Cash Cows, delivering steady unit volumes in a mature market and generating predictable margins after amortizing development costs years ago.
These assets produced roughly $45–55 million in annual net cash flow during 2023–2024, helping fund restructuring and drove a 12% improvement in operating cash conversion in that period.
- Steady demand: mature CNS indications, low volatility
- High efficiency: minimal R&D, gross margins ~60% in 2024
- Financial role: funded turnaround, ~$50M cash contribution 2023–24
Lannett’s cash cows: $350–360M revenue, ~$150M funding, 35–60% gross margins
Levothyroxine, cardiovascular generics, oxybutynin, opioid generics, and legacy CNS drugs acted as Lannett’s cash cows in 2024–25, collectively generating ~ $350–360M annual revenue and funding ~$150M of restructuring, R&D, and debt service while carrying gross margins of 35–60% across lines.
| Product | 2025 Rev ($M) | Market Share | Gross Margin |
|---|---|---|---|
| Levothyroxine | 120–140 | 30–35% | ~60% |
| Cardio generics | ~80 | ~12% vol | ~45% |
| Oxybutynin | 42–48 | 18–22% | ~60% |
| Opioid generics | ~60 | 20–25% (select SKUs) | 35–40% |
| CNS legacy | 45–55 | mature | ~60% |
Full Transparency, Always
Lannett Company BCG Matrix
The file you're previewing is the exact Lannett Company BCG Matrix you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
